Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity (Q24301064)

2

0 references

Tzu-Hsuan Huang

3

0 references

Julia Piasecki

4

0 references

Tammy L Bush

5

0 references

Timothy Sullivan

6

0 references

Ian N Foltz

7

0 references

Wesley Chang

8

0 references

Heather Douangpanya

9

0 references

Thu Dang

10

0 references

Jason W O'Neill

11

0 references

Rommel Mallari

12

0 references

Xiaoning Zhao

13

0 references

Daniel G Branstetter

14

0 references

John M Rossi

15

0 references

Alexander M Long

16

0 references

Xin Huang

17

0 references

Pamela M Holland

Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family

18

0 references

language of work or name

English

0 references

publication date

11 August 2014

0 references

published in

Cancer Cell

0 references

volume

26

0 references

issue

2

0 references

page(s)

177-89

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Antibody-based fusion proteins to target death receptors in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

The Fas-FADD death domain complex structure unravels signalling by receptor clustering

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

E2 interaction and dimerization in the crystal structure of TRAF6

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Targeting death-inducing receptors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Three-dimensional structure of a human immunoglobulin with a hinge deletion

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Death receptor agonists as a targeted therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

A first-in-human study of conatumumab in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2014.04.028

7 January 2021

10.1016/J.CCR.2014.04.028

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1613075

1613075

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference